These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2990 related items for PubMed ID: 22508812

  • 1. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.
    J Clin Oncol; 2012 May 20; 30(15):1796-804. PubMed ID: 22508812
    [Abstract] [Full Text] [Related]

  • 2. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.
    J Clin Oncol; 2011 Sep 01; 29(25):3351-7. PubMed ID: 21788566
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.
    Cancer; 2010 Mar 15; 116(6):1431-9. PubMed ID: 20131351
    [Abstract] [Full Text] [Related]

  • 4. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.
    Oncology; 2011 Mar 15; 80(5-6):341-9. PubMed ID: 21791944
    [Abstract] [Full Text] [Related]

  • 5. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan 15; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 7. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.
    J Clin Oncol; 2011 Jun 01; 29(16):2150-7. PubMed ID: 21519019
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.
    Arch Gynecol Obstet; 2009 Jul 01; 280(1):43-8. PubMed ID: 19082617
    [Abstract] [Full Text] [Related]

  • 9. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G, Loibl S, Maisch A, Untch M.
    Breast; 2011 Oct 01; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 04; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Aug 04; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 13. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.
    Breast Cancer Res Treat; 2012 Apr 04; 132(3):793-805. PubMed ID: 21562709
    [Abstract] [Full Text] [Related]

  • 14. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S.
    Breast Cancer Res Treat; 2010 Nov 04; 124(1):133-40. PubMed ID: 20697801
    [Abstract] [Full Text] [Related]

  • 15. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.
    Cancer; 2010 Sep 15; 116(18):4227-37. PubMed ID: 20549829
    [Abstract] [Full Text] [Related]

  • 16. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C.
    Breast Cancer Res Treat; 2011 Nov 15; 130(2):477-87. PubMed ID: 21837479
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM.
    J Clin Oncol; 2006 Mar 01; 24(7):1037-44. PubMed ID: 16505422
    [Abstract] [Full Text] [Related]

  • 18. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 19. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.
    J Surg Oncol; 2002 May 01; 80(1):4-11. PubMed ID: 11967899
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.
    J Clin Oncol; 2010 Apr 20; 28(12):2024-31. PubMed ID: 20308670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 150.